Mogrify, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, has extended its Series A financing round to £38 million. The Cambridge firm says the funding will support further advancement of Mogrify’s pipeline through pre-clinical translation, continued platform optimisation, and facilitation of new and existing biopharma collaborations. … Continue reading MedTech Mogrify extends Series A financing to £38m